# Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients

> **NCT00922688** · NA · UNKNOWN · sponsor: **Medical Center Alkmaar** · enrollment: 30 (estimated)

## Conditions studied

- Colon Carcinoma

## Interventions

- **DRUG:** Dipeptide Alanyl-Glutamine
- **DRUG:** Placebo
- **DRUG:** Dipeptide Alanyl-Glutamine

## Key facts

- **NCT ID:** NCT00922688
- **Lead sponsor:** Medical Center Alkmaar
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-12
- **Primary completion:** 2012-12
- **Final completion:** 2013-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2011-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00922688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00922688, "Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00922688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*